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Abstract: Five new Au(III)-peptidodithiocarbamato complexes of the 
type [AuIIIBr2(dtc-AA1-AA2-OR] (AA1=Sar, L/D-Pro; AA2=L/D-Ala, Aib; 
R=OtBu, TEG), differing in the amino acidic sequence and/or the 
chiral amino acid configuration, were designed to enhance the tumor 
selectivity and bioavailability. The gold(III)-based moiety was 
functionalized to exploit the targeting properties of the  peptidomimetic 
ligand towards  two peptide transporters (namely, PEPT1 and PEPT2), 
up-regulated in several tumor cells. The compounds were synthesized 
and fully characterized, mainly by means of elemental analysis, one 
and two dimensional NMR spectroscopy, FT-IR and UV-Vis 
spectrophotometries. The crystal structures of three compounds were 
also solved by X-ray diffraction. In vitro cytotoxicity studies using a 
panel of human tumor cell lines (A549, MCF-7, A2780, H1975, H460 
and A431) showed that the dtc-Pro-Aib-OtBu derivative is very 
effective, with GI50 values much lower than those of Cisplatin. It was 
thus selected for evaluating the stability under physiological 
conditions and possible interaction with serum albumin as well as for 
PARP-1 enzyme inhibition assays and preliminary ex vivo toxicity 
experiments on healthy rat tissues.  
Introduction 
Cisplatin, cis-diamminodichloridoplatinum(II), since the 
serendipitously discovery of its antiproliferative activity by 
Rosenberg in 1968, is still one of the most used metal-based 
drugs in anticancer therapy.[1]  
In spite of its significant antitumor activity, its use is generally 
limited by the poor selectivity toward malignant cells. Indeed, 
Cisplatin is toxic also to normal tissues, mainly causing nausea, 
anorexia, alopecia, and most of all nephro-, oto- and 
neurotoxicity.[2] Moreover, the activation of resistance 
mechanisms, which can be either intrinsic or acquired after some 
cycles of therapy,[3-5] make Cisplatin inactive against  some tumor 
types, narrowing its spectrum of action. Despite these restrictions, 
it is still administered to patients to treat testicular cancer and, in 
combination with other chemotherapeutics, some ovarian, small 
cell lung, bladder and breast tumors.[6]  
The poor chemotherapeutic index of this widely clinically-used 
drug gave rise to the development of second- and third- 
generation platinum-based derivatives and opened the frontiers 
to the design of new anticancer drugs based on alternative  
metals.[7-9] In particular, the research has focused on the 
synthesis of new complexes with better selectivity for cancerous 
cells and, consequently, with less side effects.[10] 
In our research group, new “first generation" Au(III)-
dithiocarbamato compounds with  general formula [AuIIIX2(dtc)] 
(X= Cl, Br; dtc= various dithiocarbamates) were designed and 
prepared. Interestingly, these compounds showed outstanding 
antiproliferative activity both in vitro towards different human 
cancer cell lines and in vivo against murine tumors and human 
xenografts.[11] Moreover, neither cross resiatance nor the  main 
drawbacks of cisplatin-based therapy were detected.. Indeed, in 
the last years it was demonstrated that Au(III)-dithiocarbamato 
complexes exploit a mechanism of action different from that of the 
clinically-established platinum drugs.[11-12] These promising 
results represented the starting point for the development of new 
"second generation" compounds, designed to improve the 
bioavailability, tumor selectivity and cellular uptake [13-15] 
compared to the previously synthesized compounds. New 
complexes of the type [AuIIIX2(op-dtc)] (X= Cl, Br; op-dtc= various 
oligopeptide dithiocarbamates) were prepared, of which 
oligopeptides could be recognized and up-taken by specific 
peptide transporters called PEPTs (PEPT1 and PEPT2).[16-17] 
Such proton-coupled integral membrane proteins belong to the 
SLC (SoLute Carrier) family of transporters. They can co-
transport H+ ions and substrates across the cell membrane, 
creating an inward-directed proton gradient that provides the 
driving force for the accumulation of a substrate in the cell against 
its concentration gradient.[18] They are predominantly present in 
epithelial cells of small intestine, mammary glands, lung, choroid 
plexus and kidney. A unique feature of these transporters is their 
capability for sequence-independent transport of most possible 
di- and tripeptides.[18-19] In addition to their physiological 
substrates, PEPTs also mediate the membrane transport of many 
pharmacologically active peptidomimetic drugs and prodrugs, 
such as β-lactam antibiotics, angiotensin-converting-enzyme 
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(ACE) inhibitors, renin inhibitors, thrombin inhibitors, or the 
anticancer drug bestatin, owing to their structural resemblance to 
di- and tri-peptides.[20-21] 
The rationale of our choice to functionalize the metal center with 
dipeptides relies on the possibility of increasing selectivity 
towards cancer cells and the cell uptake via recognition of the 
organic tail by PEPTs, being overexpressed in some human 
cancer types.[22-24] To accomplish this strategy, we recently 
synthesized and characterized five novel complexes of general 
formula [AuIIIBr2(dtc-AA1-AA2-OR)] (Figure 1) where AA1=Sar 
(Sar= N-methylglycine), L/D-Pro; AA2=L/D-Ala, Aib (Aib= α-
aminoisobutyric acid) and R=OtBu, TEG (triethylene glycol methyl 
ether). One of them was selected as a model compound for 
evaluating the solution stability in different media and its possible 
interaction with serum albumin.  
In this work, two elements of novelty appear with respect to the 
previously synthesized compounds:[13-14] (i) the replacement of 
Sar with Pro, the only coded amino acid having a secondary 
amine; (ii) the use of both L and D-configurated amino acids to 
analyze the role of the amino acid chirality, which might affect both 
transporter recognition and mechanism of action. All compounds 
were tested in vitro against a panel of human tumor cell lines. The 
biological evaluation of these new complexes was followed by 
preliminary evaluation of toxicity, carried out by their ex vivo 
incubation with healthy rat tissues using the so called "precision-
cut tissue slices" technique. This technique is an FDA-approved 
model for drug toxicity and metabolism studies.[25-32] With respect 
to the investigation of the mechanism of action, in the last years 
there is increasing interest about PARP (poly(ADP-ribose) 
polymerase) inhibitors as anticancer agents, including Au(III) 
compounds, [33-37] since a cascade of apoptosis-promoting signals 
starts upon enzyme inactivation. These inhibitors can be either 
used alone or in combination with other well-established DNA-
damaging drugs, thus amplifying their cytotoxic effect.[38-40]  
Based on this scientific and clinical interest, this work also focused 
on the interaction of our compounds with PARP-1. Notably, the 
nuclear levels of PARP-1 in human breast cancer (especially in 
triple-negative tumors) have been directly correlated to the stage 
of progression of the malignant transformation, representing a 
parameter to predict poor prognosis.[41-45]  
 
 
Results and Discussion 
Chemistry 
 
Synthesis. We synthesized the five novel gold(III) dipeptido-
complexes reported in Figure 1. The choices of the amino acid 
residues and ester type were made taking into account the 
previous results obtained for similar compounds, in which the 
dithiocarbamato moiety was functionalized with esterified 
oligopeptide chains, whose length ranged from 2 to 5 amino 
acids.[13-14] In the complexes IT01, IT02 and IT05 (Figure 1) the N-
terminus amino acid is Sar whereas in IT03 and IT04 it is the N,N-
disubstituted amino acid proline (Pro). This replacement was 
made to investigate the effect of the rigidity on the antiproliferative 
activity of the final compounds.  
The chosen C-terminus amino acids were selected to be Ala or 
Aib in light of the promising results collected for the Gly- and Aib-
containing compounds AuD6 and AuD8.[15] In particular, Ala was 
selected because of its intermediate properties between Aib and 
Gly.  
   
 
Figure 1. Chemical structures of the dipeptides P1-P5 and the corresponding 
gold(III)-dithiocarbamato complexes (IT01-IT05).  
 
Concerning the C-terminus of the dipeptides, the carboxyl 
function was esterified as we previously observed that a free – 
COOH group is detrimental to stability and antiproliferative activity. 
A screening between -OMe, -OEt and -OtBu esters demonstrated 
that the higher the hydrophobic character and sterically-hindered 
nature of the ligands, the greater the biological activity of the final 
Au(III) complexes.[14] Therefore, in this work the tert-butyl ester 
was chosen as a C-terminus group. On the other hand, a higher 
hydrophobicity lowers the solubility in aqueous media, a problem 
for the administration of the complexes in vivo. Thus, a TEG-
functionalized gold(III) complex was prepared to enhance the 
water solubility due to the presence of ethyloxy-groups (Figure 1), 
while maintaining the steric hindrance at the C-terminus of the 
complex. The synthesis of the hydrochloride esterified dipeptide 
derivatives HCl.H-Sar-L/D-Ala-OtBu (P1 and P2, respectively), 
HCl.H-L/D-Pro-Aib-OtBu (P3 and P4, respectively) and HCl.H-
Sar-Aib-OTEG (P5) was performed using classic solution 
synthesis reagents and procedures, according to the Scheme 
S1.[46-49]  
After liquid chromatography and crystallization purification, the 
dipeptides were deprotected at the N-terminus by catalytic 
hydrogenation over Pd/C. The Z (benzyloxycarbonyl) N-
protecting group was used for its stability and clean removal by 
catalytic hydrogenolysis. After Z-removal, the dipeptides were 
turned into their more stable hydrochloride salts by treatment with 
HCl in diethylether solution. The hydrochloride dipeptides were 
then directly used for the synthesis of the corresponding gold(III) 
dithiocarbamato complexes: [AuIIIBr2(dtc-Sar-L/D-Ala-OtBu)] 
    
 
 
 
 
 
(IT01 and IT02, respectively), [AuIIIBr2(dtc-L/D-Pro-Aib-OtBu)] 
(IT03 and IT04, respectively) and [AuIIIBr2(dtc-Sar-Aib-OTEG)] 
(IT05) (Scheme 1, Figure 1). Despite extensive efforts, we were 
not able to isolate the free dithiocarbamato ligand in a stable form. 
Thus, a one-pot approach was adopted for the synthesis of the 
complexes. The dithiocarbamato ligand was generated in situ, 
treating the water solution of the hydrocloride dipeptide with 
NaOH and 2 equivalents of CS2 in an ice bath. After the 
dithiocarbamato derivative formation, the ligand solution was  
immediately added to a water solution containing 0.5 eq. of 
KAuBr4, leading to the precipitation of yellow ochre-brown 
powdery solids. The complexes were washed with cold water and 
then purified through flash chromatography.  
 
Scheme 1. General synthetic route for the synthesis of gold(III) dithiocarbamato 
complexes IT01-IT05. (IT01/02 R1= CH3; R2=H; R3=CH3; R4=H; R5= -tBu. 
IT03/04 R1+R2= -(CH2)3-; R3= R4=CH3; R5= -tBu. IT05: R1= CH3; R2=H; R3= 
R4=CH3; R5= -TEG). A= H2O, 0°C; B=KAuBr4, H2O, 0°C. 
Characterization. The dipeptides (P1-P5) and the corresponding 
gold(III)-dithiocarbamato derivatives (IT01-IT05) were 
characterized by means of different techniques, which confirmed 
the obtainment of the designed structures.  
The stoichiometry of the final compounds was checked through 
elemental analysis, while their thermal behavior was investigated 
by thermogravimetric (TG) and differential scanning calorimetric 
(DSC) analyses (Table S1). A good correlation was detected 
between experimental and calculated (to metallic gold) weight 
loss values for all the compounds. 
Regarding the structural characterization, data collected by FT-IR 
spectrophotometry and mono and bidimensional NMR 
spectroscopy proved particularly useful to characterize the 
synthesized complexes (Table 1 and Tables S2-S3).  
The discussion of the FT-IR analysis (Table S2) is reported in the 
Supporting Information[50-55].  
The synthesized dipeptides P1-P5 and the corresponding gold(III) 
complexes IT01-IT05 were further characterized by means of 
both mono (1H, Table 1) and bidimensional  ([1H,13C] HMBC, 
Table S3) NMR analysis.  
In general, all proton signals of the dipeptide backbone undergo 
a downfield shift upon complexation, less evident when the 
distance from the metal center increases (Table 1). The protons 
located in the -NCSS proximal groups display a chemical shift 
increase of about 0.5 to 1 ppm, while the amide signal follows an 
opposite trend, being upfield-shifted by 0.1-0.2 ppm for the 
complexes with respect to the free dipeptides. Similarly, a 
downfield-shift trend is detected also for the 13C atoms directly 
bonded to the –NCSS moiety (Table S3), with a  increase of 
about 7 ppm on passing from the free peptides to the 
corresponding complexes.   
The formation of the dithiocarbamato moiety is confirmed by the 
disappearance of the free amine proton signal of the 
hydrochloride dipeptide (usually occurring at 9.8-9.3 ppm, Table 
1) and by the appearance of the dithiocarbamato carbon atom 
resonance at about 200 ppm (Table S3), in agreement with 
literature data for complexes with high-oxidation state metals.[56] 
Both the 1H and the [1H,13C]-HMBC NMR spectra of the 
complexes (the spectra of the complex IT01 are reported as an 
example in Figures S5, S6 and S7) show a double resonance for 
the nuclei within or closest to the dithiocarbamic moiety (e.g., the 
dithiocarbamic carbon -CSS at about 200 ppm and the protons of 
the N-CH3 and N-CH2 groups of the sarcosine residue in Figure 
S7), as already observed for similar compounds.[13, 14] This 
phenomenon was recently explained by the presence of two 
different isoforms of the compounds (in dynamic equilibrium in 
solution).[57]  
 
Table 1. 1H NMR spectral data of the starting dipeptides P1-P5 (HCl·H-AA1-
AA2-OR: AA1= Sar, L/D-Pro; AA2=D/L-Ala, Aib; R= -tBu, TEG) and the 
corresponding gold(III)-dithiocarbamato derivatives IT01-IT05 ([AuIIIBr2(dtc-
AA1-AA2-OR])  (DMSO-d6, 298 K, 300 MHz).  
Compo
und 
δ (1H) [ppm] 
 -OR AA1 AA2 -NH2+ 
 R=tBu AA1=Sar AA2=L-Ala  
P1 1.40(-C(CH3)3) 2.53 (N-CH3) 1.28 (β-CH3) 9.00 
  3.70 (N-CH2) 4.17 (α-CH)  
   8.88 (NH)  
IT01 1.40(-C(CH3)3) 3.37 (N-CH3) 1.23 (β- CH3) - 
  4.53 (N-CH2) 4.18 (α-CH)  
   8.79 (NH)  
 R=tBu AA1=Sar AA2=D-Ala  
P2 1.40(-C(CH3)3) 2.52 (N-CH3) 1.27 (β- CH3) 9.12 
  3.69 (N-CH2) 4.16 (α-CH)  
   8.96 (NH)  
IT02 1.41(-C(CH3)3) 3.36 (N-CH3) 1.28 (β-CH3) - 
  4.53 (N-CH2) 4.17 (α-CH)  
   8.79 (NH)  
 R=tBu AA1=L-Pro AA2=Aib  
P3 1.32(-C(CH3)3)  1.83(CH3'', 
CH24) 
1.36 (β- CH3) 9.80 
  2.27 (CH3') 8.92 (NH)  
  3.15 (CH25)   
  4.11 (CH2)   
IT03 1.38(-C(CH3)3) 2.08(CH3'', 
CH24) 
1.33 (β- CH3) - 
  2.41 (CH3') 8.75 (NH)  
  3.88 (CH25)   
  4.76 (CH2)   
 R=tBu AA1=D-Pro AA2=Aib  
P4 1.37(-C(CH3)3) 1.83(CH3'', 
CH24) 
1.37 (β- CH3) 9.34 
  2.29 (CH3') 8.94 (NH)  
  3.15 (CH25)   
  4.14 (CH2)   
IT04 1.38(-C(CH3)3) 2.10(CH3'', 
CH24) 
1.31 (β- CH3) - 
  2.41 (CH3') 8.78 (NH)  
  3.89 (CH25)   
  4.76 (CH2)   
    
 
 
 
 
 
 T=TEG AA1=Sar AA2=Aib  
P5 3.24 (O- CH3) 2.51 (N- CH3) 1.39 (β-CH3) 9.04 
 3.41-3.54 
(CH23,4,5,6) 
3.66 (N- CH2) 9.04 (NH)  
 3.57-3.60 (CH22)    
 4.10-4.13 (CH21)    
IT05 3.24 (O- CH3) 3.57 (N-CH3) 1.39 (β-CH3) - 
 3.36-3.58 
(CH23,4,5,6) 
4.47 (N-CH2) 8.83 (NH)  
 3.62-3.65 (CH22)    
 4.10-4.11 (CH21)    
 
Crystal Structures 
The complexes IT05, the racemate IT03/IT04 and the urethane-
protected precursor of a peptide ligand, namely Z-L-Pro-Aib-OtBu, 
were characterized by single crystal X-ray diffraction analysis.   
The molecular structure of IT05 is reported in Figure 2. The metal 
exhibits a square planar geometry achieved by the S,S chelate 
dithiocarbamato (dtc) ligand and by two bromide. The 
coordination environment of the metal and the coordination 
distances (Tables S4-S5) are in agreement with previously 
reported data for gold complexes with a dtc ligand and two 
bromide ligands. The peripheral methylated triethylene glycol is 
folded towards the dtc moiety and the three ethereal oxygen 
atoms, O(4)-O(6), are capping the C(2) methyl group of the dtc 
ligand. The crystal packing shows that the IT05 molecules are 
irregularly stacked along the b crystallographic axis (Figure S8), 
and that the long arm of the ligand originating from the C(3) atom, 
is responsible of several C-H∙∙∙O interactions (Figure S9). In 
addition, there is a bifurcated hydrogen bond between the N(2)-H 
and the O(4)’ and O(5)’ atoms of a symmetry related triethylene 
glycol residue (symmetry code = 1/2-x; 1/2+y; z), d[N(2)∙∙O(4)’] = 
3.00(3) Ǻ, and d[N(2)∙∙O(5)’] = 3.18(4) Ǻ, which is mainly 
responsible for the conformations adopted by the methylated 
triethylene glycol. 
 
Figure 2. Molecular structure of [AuIIIBr2(dtc-Sar-Aib-OTEG)] (IT05). CCDC 
Number: 1001852; CIF data block name: data_it05pen; Formula: C15 H27 Au1 
Br2 N2 O6 S2; Unit Cell: a 22.15(2) b 9.599(9) c 25.88(2); Space Group: Pbcn. 
Attempts to grow single crystals from the chiral compound IT03 
were fruitless. We therefore decided to explore the racemic 
crystallography approach, based on the principle that, in general, 
racemates are more easily amenable to crystallization than the 
corresponding enantiopure compounds.[58-61] Equimolar amounts 
of the two enantiomers IT03 and IT04 were combined for 
crystallization experiments, one of which (from acetone) was 
successful. In the structure of the racemate IT03/IT04 (Figure 3), 
the planar square geometry and the metal coordination distances 
(Tables S6-S7) closely match those observed for IT05. The C 
and C atoms of the Pro residue are coplanar to the sulfur atoms. 
In the L enantiomer, taken as the asymmetric unit, the values of 
backbone torsion angles of the peptide moiety are indicative of a 
semi-extended [or poly(Pro)n II] conformation for the Pro residue, 
while right-handed helical for Aib. The Aib N-H group is H-bonded 
to the C=O group of a disordered, co-crystallized acetone 
molecule within the same asymmetric unit. In the packing mode, 
acetone molecules occupy infinite channels that run parallel to the 
b direction (Figure S10). 
The X-ray diffraction structure of Z-L-Pro-Aib-OtBu has been 
solved as well (Supporting Information, Figure  S11 and Tables 
S8-S10). Interestingly, the conformations adopted by the L-Pro 
and Aib residues are very similar to those observed for the L-
enantiomer of the racemate IT03/IT04.  
 
    
 
 
 
 
 
 
Figure 3. Molecular structure of AuIIIBr2(dtc-L,D-Pro-Aib-OtBu (IT03/IT04). The 
L enantiomer is shown (IT03). H-atoms have been omitted for clarity. 
UV-Vis analysis of stability under physiological conditions 
Since the compounds are not per se water soluble, all the 
biological assays have been performed via pre-dissolution in 
DMSO (at a final maximum concentration of 1 % v/v) prior to 
addition to cell culture medium. Among our gold(III)-
peptidedithiocarbamato derivatives, IT03 was chosen as a model 
compound for first evaluating the stability in pure DMSO (used as 
stock solution). The compound was dissolved in the organic 
solvent at a final concentration of 50 µM, and the UV-Vis spectra 
were recorded at 25°C in the range 190-800 nm over 24 h (Figure 
S12). In this solvent, the complex shows three main absorption 
bands. The first two bands, hereinafter called band I and band II, 
are assigned from the literature to intraligand π*← π transitions 
(at about 260 and 310 nm) mainly located on the -NCS and -CSS 
moieties, respectively.[62-63] An intraligand π*←n transition (where 
n is the in-plane non-bonding sulfur orbital) is expected around 
340 nm, but is not discernible due to  overlap  with higher intensity 
bands at very close wavelength. The third detectable band of 
weak intensity is rather found at higher wavelengths (around 370 
nm), and is assigned to an electron transfer of the type u←g, from 
a 4p orbital (π symmetry) of the bromide ligands to the lowest 
unfilled 5d metal orbital (band III, Table S11).[64] 
No significant modification of the position and/or intensity of the 
bands was detected over 24 h, thus highlighting the compound 
stability in this solvent. The only very slight variations observed 
are due to the presence of water in the system, which increases 
over time and results in partial hydrolysis of the complex. The 
bromide ligands are thus substituted by one/two water molecules 
to form the corresponding aquo complex, which is still quite water 
soluble. This phenomenon is associated with a slight shift in the 
wavelength of the two main absorption bands, which move 
towards the band positions recorded for the same complex in 
water (DMSO concentration < 5% v/v).  
Moving to aqueous systems, the behavior in pure deionized water 
was first evaluated, confirming the tendency of the complex to 
undergo partial hydrolysis, with slow modifications over the first 
24 h (Figure S13). The main absorption bands present opposite 
trends, with band I and band II undergoing hypochromic and 
hyperchromic modifications with time, respectively. 
Simultaneously, a band at nearly 380 nm increases in intensity 
with time. All these changes are ascribed to the formation of the 
aquo-complex. Anyway, after nearly 10 h, an hypochromic effect 
of the absorption bands II and III is detected, which can be 
correlated to the partial precipitation of the dihydroxo-complex 
(already described for other gold(III)-dithiocarbamato 
derivatives)[65] which is less water soluble than the corresponding 
aquo complex. The compound, which precipitates as a yellow 
powdery solid, was isolated and characterized by means of 
elemental analysis and FT-IR spectroscopy, and finally identified 
as the hydroxo-derivative. 
The behavior of the complex IT03 in saline solution (0.9% w/v 
NaCl) is slightly different compared to that recorded in pure water 
(Figure S14, Table S11). In this case, an hyperchromic effect is 
detected for both the bands I and II. The hyperchromic effect 
recorded for the two main bands can be explained with the 
substitution of the bromide ligands with chlorides, as a 
consequence of the higher concentration of Cl- ions in solution. 
Subsequently, the replacement of one/two chloride ligands with 
water molecules can lead to the formation of the mono/di-aquo-
derivative, as suggested by the appearance of an absorption band 
at 380 nm (metal-to-ligand charge transfer). However, in this case 
no precipitate was detected in solution over 24 h.  
The behavior of IT03 in PBS (phosphate buffered solution) is 
completely different with respect to the previous ones (Figure S15, 
Table S11). During the first 4 h from dissolution the complex 
undergoes fast hydrolysis and the dihydroxo complex precipitates 
as a yellow powdery solid. The more basic pH of the solution 
(buffered at 7.4) and the presence of phosphato ions can favor 
the formation and precipitation of the dihydroxo derivative and the 
corresponding phosphato-derivative. 
Moving to more complex environments, the stability of the gold(III) 
complex in complete cell culture medium was analyzed. The 
electronic spectra, recorded in PBS added of 20% v/v complete 
medium (RPMI-1640 medium supplemented with 10% fetal calf 
serum), show two main absorption bands at 273 and 307 nm, both 
assignable to the IT03 complex (Figure S16). In fact, the main 
absorption band of the medium itself is detectable at 276 nm. The 
behavior of the complex in this environment is similar to that 
observed in PBS, even if a precipitate did not form in this case, 
probably as a consequence of the interaction of the complex with 
proteins or other medium components. Similarly to the previous 
spectra, an intensity reduction of the bands related to the π*← 
π transitions, is accompanied by an hyperchromic effect of the 
    
 
 
 
 
 
band at 362 nm, correlated to the formation of gold-oxygen bonds 
(as already described above). 
 
Biological activity 
 
In vitro cytotoxicity. The compounds were tested on a broad panel 
of human cancer cell lines to assess their cytotoxic activity against 
different tumor types. The GI50 values, summarized in Table 2, 
were calculated for each compound after a 72-h incubation as 
described in the Experimental section. 
All the dipeptide-functionalized gold(III) complexes show a quite 
similar activity. Notably, overall the compounds present higher 
cytotoxic activity than Cisplatin for instance towards the human 
ovarian cancer A2780 cell line, with GI50 values lower than 0.6 µM, 
thus resulting about 10 to 20 times more effective than the 
reference metallodrug. Interestingly, very  promising results were 
obtained also with H1975 cells from human non-small cell lung 
cancer, with most GI50 values in the submicromolar range. The 
compounds are also moderately active against the breast 
adenocarcinoma MCF-7 (GI50 values about 5-fold lower than that 
recorded after Cisplatin treatment). 
Among the tested complexes, IT03 and IT04 are the most active 
with an antiproliferative activity comparable to - in some cases 
higher than - that of Cisplatin. Interestingly, IT05 seems less 
potent than the other members of the series, for instance against 
the MCF-7 and H1975 cell lines. This could be ascribed to 
differences among the studied compounds in hydrophobicity and 
steric hindrance at the C-ter, IT05 bearing a TEG ester group 
instead of a tert-butyl one. 
Taken together, the observed antiproliferative potency of the new 
complexes resulted comparable or slightly less pronounced than 
that of the "first generation" compound AuL12 ([AuIIIBr2(ESDT)], 
(ESDT = ethylsarcosinedithiocarbamate) against all the tested 
cell lines. 
Table 2. GI50 ± st.dev. (µM) recorded after a 72-h treatment against the A549 
(human non-small cell lung carcinoma), MCF-7 (human breast cancer), 
A2780 (human ovarian carcinoma cells), H1975 (human non-small cell lung 
cancer), H460 (human large cell lung carcinoma) and A431 (human 
epidermoid carcinoma) cell lines for the compounds IT01-05, AuL12 and 
Cisplatin (taken as a reference). The data correspond to means of at least 
three experiments performed in quadruplicate  S.D. 
 GI50 ± st.dev. (μM) 
 
IT01 IT02 IT03 IT04 IT05 AuL12 Cispla
tin 
A54
9 
20±3 27±3 10±3 9±2 14±2 12±2 8.0±0.
5 
MC
F-7 
3.4±
0.9 
4.3±
0.8 
4.0±
0.7 
3±2 8.5±
0.9 
6.4±0.7 20±3 
A27
80 
0.6±
0.2 
0.3±
0.2 
0.4±
0.1 
0.2±0.
1 
0.5±
0.1 
0.40±0.0
8 
5±2 
H19
75 
0.6±
0.1 
0.6±
0.2 
0.7±
0.1 
0.66±0
.06 
6±1 0.158±0.
008 
0.99±0
.09 
H46
0 
4±2 3.4±
0.4 
3.6±
0.5 
3.0±0.
6 
4.3±
0.2 
2.2±0.3 0.8±0.
1 
A43
1 
16±4 14±3 8±3 10±2 13±3 10 ± 3 3.2± 
0.5 
 
Generally, the compounds differing only in the stereochemical 
configuration of the chiral amino acid (D, L enantiomers) in the 
dipeptide ligand, show similar cytotoxic activity (IT02 vs IT01 and 
IT04 vs IT03). This highlights that there is no correlation between 
the stereochemical features of the compounds and their cytotoxic 
activity and/or cell transporter recognition. Nevertheless, the 
PEPT selectivity for L-configuration derivatives is proved for 
naturally occurring aminoacids or oligopeptides but PEPTs are 
responsible also for the transport of peptido-mimetics which only 
resemble the main features of their physiological substrates,[14-19, 
51-53] so it is possible that similar recognition occurs for both the 
gold(III) isomers regardless of their chirality. Anyway, deeper 
studies about the overexpression of PEPTs by the selected cell 
lines will be carried out to analyze if differences in the 
internalization rates of the two gold(III) enantiomers can be 
detected. 
 
Ex vivo toxicity.  
Recently, the precision cut tissue slices technique was exploited 
to study the toxic effects of experimental anticancer 
organometallic compounds,[27-29] aminoferrocene-containing pro-
drugs,[30] ruthenium-based kinase inhibitors,[31] as well as 
supramolecular metallacages as possible drug delivery 
systems.[32] In this work, the toxicity of some selected complexes 
was tested using different tissues from rat organs ex vivo using 
the PCTS method.[25] In these tests, thin slices of healthy tissue 
derived from organs excised from animals are incubated with 
drugs or other compounds. This method allows the study of drug 
metabolism and toxicity in intact tissues, with great advantages 
with respect to both in vitro cell culture and in vivo animal testing. 
The use of slices results in a reduction of the number of animals 
used for the experiments, allowing the in-parallel assay of more 
than one compound at different concentrations. Moreover, 
although being an ex vivo context, the method has the advantage 
of using intact tissues where enzyme systems, cofactors and 
transporters are present at their physiological levels, resulting in 
a quite reliable model for the in vivo conditions.[54] 
Based on the cellular screening (Table 2), the complex IT03 is 
one of the most promising and was thus selected as a model 
compound for the ex vivo toxicity experiments. Thus, the toxicity 
of IT03 and AuL12 were evaluated in healthy rat tissues (liver and 
colon) in comparison to Cisplatin, since these two organs are 
generally mainly involved in drug metabolism and excretion, 
respectively. Moreover, the compounds were also tested against 
kidney as this organ is usually strongly affected by treatment with 
Cisplatin in patients.  
The compounds were incubated with slices and the viability of the 
tissues after a certain incubation time (24 h for liver and kidney, 5 
h for colon slices, respectively) was determined measuring the 
ATP content as described in the Experimental section. For each 
experiment, control samples were also incubated with medium 
containing the maximum concentration of DMSO used in the test 
samples, so to determine any intrinsic toxic effect of the organic 
solvent on the slice viability. Notably, the concentration of DMSO 
added to the samples proved not toxic in all the analyzed organ 
tissues with tissue viability values comparable to those of control 
samples incubated with pure medium (data not shown). Overall, 
    
 
 
 
 
 
the gold complexes displayed a concentration-dependent toxicity 
profile with TC50 values higher than Cisplatin (Table 3), made 
exception for colon slices. Furthermore, it should be noted that 
the compounds show also markedly less toxic effects in kidney 
slices with respect to the anti-rheumatic gold-based drug and 
potent cytotoxic agent auranofin.[70] 
 
Table 3. Toxicity (TC50 values) of the gold complexes IT03 
and AuL12 in comparison to Cisplatin  against liver, colon 
and kidney slices. The data are mean (± SD) values from 
at least three independent experiments.  
 TC50 ± st.dev. (μM) 
Organ IT03 AuL12 Cisplatin 
Liver 37 ± 7 44 ± 6 25 ± 2 
Colon 38 ± 9 51 ± 10 >100 
Kidney 43 ± 9  53 ± 9 13 ± 2 
 
 
Interaction with PARP-1 enzyme.  
Based on previous studies involving other gold(III) 
dithiocarbamato compounds, some biologically-relevant targets 
were identified including thioredoxin reductase (TrxR) and 
proteasome enzymes.[11, 15, 54, 71] For this class of complexes, DNA 
does not seem a major target, despite the great affinity for the 
isolated DNA molecule and the capability to inhibit both RNA and 
DNA synthesis in a non dose-dependent way, differently from 
what recorded for Cisplatin.[11]  Nonetheless, other proteins 
involved in DNA repair and regulation mechanisms could be 
affected by the treatment with our new anticancer agents. Within 
this framework we investigated the interaction of the compounds 
IT03 and AuL12 (our reference "first generation" complex) with 
PARP-1, a zinc-finger protein essential for the DNA repair process 
and with a key role in the mechanisms of cancer cell resistance 
to Cisplatin.  
Among the PARP inhibitors worldwide studied, Olaparib 
(Lynparza®, AstraZeneca), showed an IC50 value of 0.005 µM in 
the in vitro inhibition of the PARP-1 enzyme,[40] and is now 
approved by the US Food and Drug Administration for the 
treatment of advanced ovarian cancer in patients with germline 
BRCA-mutations. It is also under clinical studies for the treatment 
of triple negative breast cancer and metastatic castration-
resistant prostate cancer. In this context, it is worth highlighting 
that nuclear levels of PARP-1 have been directly correlated to the 
stage of progression of the malignant transformation, 
representing a parameter to predict poor prognosis.[41] In addition, 
PARP-1 is directly involved in the angiogenic process[42] and 
contributes to the regulation of important transcription factors, 
such as NFkB,[43-45] whose overexpression is connected to 
neoplasia progression and malignancy.  
Our gold compounds were tested as inhibitors of PARP-1 (purified 
protein) as previously reported, and the collected values (Figure 
4) were compared with those obtained for Cisplatin and the 
inhibitor Olaparib®.[40] It is worth mentioning that while the gold 
complexes could be incubated for only 1 h with PARP-1 due to 
their fast kinetic of ligand exchange, Cisplatin required at least 24 
h to reach the maximum of inhibition.  
Figure 4. Inhibition of the PARP-1 activity by test compounds, also reported in 
Table S12 The data correspond to means of at least three experiments 
performed in triplicate  S.D. 
 
Both our gold(III)-dithiocarbamato complexes IT03 and AuL12 
proved good inhibitors of the purified PARP-1 enzyme, with 
similar IC50 values in the nanomolar range (Figure S17), in 
accordance with previously reported results on other families of 
Au(III) complexes. [35,37]  Interestingly, the results collected after 
1-h incubation for the gold(III) compounds are comparable to 
those obtained for the PARP-1 inhibitor Olaparib® after 24 hours 
of incubation, thus highlighting a high and fast reactivity of our 
compounds towards this DNA repair protein.  
If comparing the results obtained for the new compound IT03 with 
Cisplatin, of which IC50 is about 700-fold higher, with this work we 
find again differences in terms of biological targets and/or 
mechanism of action between our gold(III) complexes and the 
reference anticancer metallodrug.  
 
Interaction with BSA  
In drug development, it is essential to analyze the interaction of 
the best selected compound with serum albumins as they are the 
most abundant proteins in the circulatory system (30-50 g/L in the 
human serum, 52-60% of plasma protein composition).[72]  
Albumins play a fundamental role not only in the control of the 
osmotic blood pressure, but also in the transport of various 
endogenous compounds, such as fatty acids, hormones, toxic 
metabolites (e.g., bilirubin), bile acids and amino acids. In recent 
years, the human serum albumin (HSA) has been emerging as a 
reliable and versatile carrier for therapeutic and diagnostic agents, 
owing to its small size, flexibility and high abundance in the 
plasma.[73-74]   
Compared to HSA, the more easily available bovine serum 
albumin (BSA) shares a sequence homology of 76%, and is 
constituted by a single polypeptide chain of 583 amino acid 
residues, having molecular weight of about 66 kDa and a 
secondary structure predominantly in the α-helix form (74%, PDB: 
3V03). Both proteins show the presence of a Trp in the subdomain 
IIA (W214 for HSA and W213 for BSA). The fundamental 
difference between HSA and BSA consists mainly in an additional 
    
 
 
 
 
 
tryptophan residue (W134) located on the surface of the BSA 
protein.[75]  
Considering the pharmacokinetic and pharmacological 
implications, the study of the interaction between new molecular 
entities and the BSA (taken as a model) becomes of great 
importance. In this regard, for many drugs and prodrugs it was 
demonstrated that this carrier protein plays a crucial role in their 
stabilization and transport, modulating their bioavailability and 
toxicity.[76]  In fact, i.v. administered metal-based therapeutics 
likely interact with serum albumin. Platinum-based drugs bind to 
HSA, thus affecting their metabolism, body distribution and 
activity.[76,77] Indeed, the protein contains six methionine residues 
(i.e., Met-87, 123, 298, 329, 446, and 548) among which the Met-
298 is the most accessible on the surface and identified as the 
main cisplatin-binding site.[78] In the literature, there are other 
examples of studies of interaction between metal-based agents 
and serum albumin.[79, 80]  
In this work, the possible interaction of the compound IT03 with 
BSA was investigated by different spectrophotometric techniques, 
namely fluorescence, UV-Vis and CD. First, the compound was 
incubated with BSA at equimolar ratio (30 μM), and electronic 
spectra were recorded over time. The UV-Vis spectrum of BSA is 
characterized by two main absorption bands at 198 and 280 nm, 
which correspond to π*← π transitions located on the peptide 
moiety and the aromatic ring of the aminoacids Trp and Tyr, 
respectively. In the UV-Vis spectrum recorded soon after the start 
of incubation, the main absorption bands previously described for 
IT03 are detected, with the band I almost overlapping to the BSA 
absorption at 280 nm (Figure S18). 
Upon incubation with BSA, no stabilizing effect (able to reduce the 
complex hydrolysis rate) seems to take place, as an hypochromic 
effect is observed for both bands I and II. This is paralleled by a 
slight increase in band intensity at 360 nm, probably due to 
complex-protein interactions via metal coordination, thus 
preventing the precipitation of the hydrolized compound.   
The interaction with BSA was analyzed also by circular dichroism 
by observing possible secondary-structure modifications upon 
incubation with the complex. The CD spectra recorded soon after 
the incubation of IT03 (after pre-dissolution in DMSO; final DMSO 
concentration < 1.5 v/v %) with BSA (15 μM) in PBS solution at 
different molar ratios (Figure  S19) showed variations in the 
protein secondary structure which were significant only at 
IT03:BSA molar ratio of 1 or higher. These spectral modifications 
can be correlated with a more extended conformation, or to an 
increase in β-sheet or random contributions to the structure. 
Anyway, this behavior is detectable only at high complex 
concentrations (with respect to BSA) that are far from the 
physiological-like conditions. 
Further studies, aimed at elucidating the results obtained with the 
CD experiments, were carried out recording fluorescence spectra 
at constant temperature (25 °C) at the same concentrations and 
time ranges reported above. In this regard, it is known that the 
intrinsic fluorescence of BSA stems from two tryptophan (Trp) 
residues per chain which are known to be excellent structural 
probes.[81-83] They are characterized by strong emission signals at 
room temperature and are very sensitive to the local environment. 
One residue is buried (W213) inside the protein whereas the 
second one is  located on the protein surface (W134). Thus, a 
change in either fluorescence intensity or emission band position 
can be correlated to a structural modification upon interaction with 
the metal-based agent.  
Here, in the first experiment the molar ratio between protein and 
IT03 was kept constant (1:1; 15 μM), and the fluorescence spectra 
were recorded at different times, starting from incubation over 24 
h. The Figures S20 and S21 show that there is a progressive 
quenching of the BSA fluorescence intensity with time. Such a 
behavior may result from a direct interaction of the coordination 
compound with the protein fluorophores or from an increasing 
amount of endogenous quenchers, such as water molecules or 
oxygen, approaching the fluorescent sites. Only slight 
modifications in terms of fluorescence intensity were detected 
while keeping the band position unaffected. Taken together, these 
results highlight that no important changes occur in the 
environmental polarity or rigidity of the two Trp upon interaction 
with IT03 at equimolar conditions. Therefore, the experiment was 
repeated changing the IT03/BSA molar ratio, recording the 
fluorescence spectra soon after the incubation at constant 
temperature of 25 °C (Figures S22 and S23). In this case, a quite 
marked decrease in the fluorescence intensity was detected with 
increasing the amount of IT03 (the DMSO content was kept 
constant for each sample). This phenomenon may be ascribed to 
either the direct interaction of the Trp134/213 with the metal-
based compound or to interactions of the compound with other 
sites of the protein, resulting in changes in local domains of the 
BSA structure, thereby justifying the observed decrease of the 
quantum yield. Based on the analysis of the spectra reported in 
Figure S22, it is worth noting that negligible modifications are 
recorded for IT03:BSA molar ratios equal to or lower than 1 
(mimicking the physiological conditions), thus suggesting that 
only a weak interaction takes place between the gold(III) complex 
and the protein. 
Conclusions  
In this work, we have preliminarily analyzed the role of the amino 
acid chirality in the biological response of the compounds along 
with the effect of substituting the Sar residue with another amino 
acid, Pro, being a derivative containing a secondary cyclic amine. 
Among the tested complexes, IT03 and IT04 proved the most 
promising with an antiproliferative activity comparable or 
sometimes greater than that of Cisplatin. Similar cytotoxic activity 
was recorded for all the investigated D, L enantiomers.  
IT03 was taken as a model compound for subsequent studies and 
its solution stability was evaluated in order to understand the 
possible modifications occurring in different aqueous systems 
mimicking the physiological conditions. The compound 
(previously solubilized in DMSO) behaves differently depending 
on the conditions. Indeed, IT03 undergoes hydrolysis both in pure 
water and in saline solution, by exchanging the bromido ligands 
with water molecules. Conversely, upon dissolution in PBS, the 
rapid formation of the hydroxo-derivative (not water-soluble) was 
detected. Anyway, when considering the cell culture medium, the 
precipitation of the hydroxo-derivative is reduced, likely due to the 
    
 
 
 
 
 
interaction of the compound with biomolecules and proteins 
present in the medium. 
It has been of fundamental importance for the forthcoming in vivo 
experiments to preliminarily evaluate if the main serum 
component can favor or interfere with the IT03 distribution and 
activity. In light of the collected results, IT03 does not significantly 
modify the secondary structure of the chosen model protein when 
incubated at low molar ratios, being representative of the 
physiological conditions. The slight modifications in serum 
albumin structure may be due to weak secondary interactions with 
the gold(III) complex, thus making HSA a possible carrier for our 
compounds in vivo.  
With respect to ex vivo studies, our results show that IT03 is less 
toxic than Cisplatin against rat liver and kidney tissues. Notably, 
concerning the liver, our gold(III) complex displayed about 50% 
lower toxicity compared to the reference drug. 
To date, the results collected for the gold-based anticancer agents 
point out the involvement of other biochemical pathways and cell 
targets with respect to Pt-based compounds.[11, 35, 84, 85]  In this 
work, the studied Au(III) complexes proved potent fast PARP-1 
inhibitors and  future experiments will be aimed at the target 
validation in more complex cellular environments, as well as at 
the elucidation whether cellular uptake actually occurs by PEPT 
transporters.  
Experimental Section 
Materials  
Acetone-d6, DMSO-d6, dichloromethane-d2, chloroform-d1, methanol-d4, 
4-dimethylaminopyridine (DMAP), triethylene glycol monomethyl ether 
(TEG-OH) (Sigma Aldrich); 1-hydroxy-1H-benzotriazole (HOBt), 
phosphoric anhydride P2O5, H-D-AlaOH, H-D-ProOH (Acros-Janssen); 
potassium tetrabromoaurate(III) dihydrate (Alfa Aesar); potassium 
hydrogen carbonate NaHCO3, potassium hydrogen sulphate KHSO4, 
sodium carbonate dodecahydrate, sodium hydroxide, sodium hypochlorite, 
sodium sulphate anhydrous, triethylamine (TEA, Carlo Erba); isobutene 
(Siad); isobutylchloroformiate (Lancaster); N-methylmorpholine (NMM), 
palladium (10% on carbon), HSarOH (Fluka); 1-ethyl-3-(3-
dimethylaminopropyl)-carbodiimide hydrochloride (EDC), N-
(benzyloxycarbonyloxy)succinimide (ZOSu, Iris Biotech); Z-Aib-OH, Z-L-
Ala-OH, Z-L-Pro-OH, Z-Sar-OH (synthesized in Prof. Formaggio 
laboratory, University of Padua). All other reagents and solvents were used 
as purchased without any further purification. 
Instrumentation  
Elemental analysis. Elemental analysis of carbon, nitrogen and hydrogen 
were obtained with a CARLO ERBA mod 1108 CHNS-O microanalyzer.  
Termogravimetric analysis. Thermogravimeter analysis (TG) and 
differential scanning calorimetry (DSC) were carried out using a 
thermoanalyzer NETZSCH mod. STA42 in the range 25-1200°C in 
alumina crucibles, with an heating rate of 5°C/min under air, with a flow 
rate of 30 cm3/min, using alumina as a reference substance. 
Thin layer chromatography. Silica gel 60 F254 (Merck) or Alugram® Sil G 
UV 254 (Macherey-Nagel) on aluminium foil was used to follow the 
reactions. Silica gel 60 F254 (Merck) on glass was used for TLC 
characterization. Retention factors (Rf) have been measured using three 
different solvent mixtures as eluents. Rf1: CHCl3/EtOH 9:1; Rf2: 
BuOH/AcOH/H2O 3:1:1; Rf3: PhMe/EtOH 7:1. Products were detected 
either by UV lamp irradiation, or with exposition to I2 vapours or by warming 
with a heat gun and spraying firstly with a 1.5 % NaClO solution and then 
with a ninhydrin-TDM solution. 
Flash chromatography. For flash chromathography (FC) purifications, 
silica gel 60 Merck (40-63 μm diameter, mesh 230-400) was used. The 
crude product was directly loaded on top of the column, after being 
dissolved in a small amount of the eluent used for the purification. 
Polarimetric measurements. Optical rotations were measured on a Perkin-
Elmer model 241 polarimeter with an Haake model D8 thermostat at the 
mercury line wavelength, using a cell with an optical pathlength of 10 cm. 
Concentrations are expressed in g/100 mL. [α] are calculated using the 
formula [α] = α/(c·l), where "c" is the concentration (in g/mL) and "l" is the 
optical path (in dm). Spectrophotometric grade MeOH was used as 
solvent. 
IR Spectrophotometry. FT-IR spectra were recorded in nujol on a Nicolet 
Nexus 870 spectrophotometer (1000 scans, resolution 2 cm-1) for the 
range 50-600 cm-1, and in solid KBr on either a Nicolet 55XC or a Perkin-
Elmer 580B spectrophotometer (32 scans, resolution 2 cm-1) for the range 
400-4000 cm-1. Data processing was carried out using OMNIC version 5.1 
(Nicolet Instrument Corp.). 
NMR Spectroscopy. All NMR spectra were acquired in the appropriate 
deuterated solvent at 298 K on a Bruker Avance DRX 300 spectrometer 
using a BBI [1H,X] probe-head equipped with z-field gradients. Data 
processing was carried out using MestReNova version 6.2 (Mestrelab 
Research S.L.). Typical acquisition parameters for 1D 1H NMR spectra 
(1H: 300.13 MHz): 16 transients, spectral width 7.5 kHz, using 32k data 
points and a delay time of 5.0 s. Spectra were processed using exponential 
weighting with a resolution of 0.5 Hz and a line-broadening threshold of 
0.1 Hz. Typical acquisition parameters for 1D 13C{1H} NMR spectra (13C: 
75.48 MHz): 8k transients, spectral width 18.8 kHz, using 32k data points 
and a delay time of 7.0 s. Sequences were optimized for 1J(13C,1H) = 145 
Hz, and 1H decoupling was achieved by using WALTZ16 pulse sequence. 
Spectra were processed using exponential weighting with a resolution of 
2.0 Hz and a line-broadening threshold of 2.8 Hz. Typical acquisition 
parameters for 2D [1H,13C] HMBC NMR spectra (1H: 300.13/13C: 75.48 
MHz): 512 transients of 16 scans/block, spectral width 7.5/18.8 kHz, 1k/1k 
data points and a delay time of 2.0 s. Sequences were optimized for 
1J(13C,1H) = 145 Hz/nJ(13C,1H) = 5 Hz with no 1H decoupling. Spectra were 
processed by using sine-square weighting with a resolution of 0.3/1.0 Hz 
and a line-broadening threshold of 0.3/1.0 Hz. 
UV-Vis spectrophotometry. Electronic spectra were recorded using a Cary 
100 Spectrophotometer (Agilent Technologies) in the range 200–800 nm 
(250-800 nm for aqueous samples containing DMSO), at a scan rate of 
300 nm min-1 and a resolution of 2 nm. Sample temperature was kept 
constant at 37°C through a Varian Dual Cell Peltier device. Data 
processing was performed with Cary WINUV version 4.2 (Varian Inc.).  
Circular Dichroism. CD measurements were acquired at 25°C with a Jasco 
J-715 spectropolarimeter (scan rate: 50 nm min-1) using Hellman quartz 
cells of 0.01 and 0.1 cm path length, respectively in the range 193–260 
and 240–350 nm. Spectra (each being the average of eight subsequent 
accumulations) were recorded at standard sensitivity (100 mdeg) with a 
data-pitch of 1 nm in the continuous mode and a resolution of 2 nm. Data 
processing was carried out using SPECTRA MANAGER version 1.52 
(Jasco Inc.), and values expressed in terms of total molar ellipticity [θ] 
(deg·cm2.dmol-1). 
Fluorescence Spectroscopy. Emission spectra were recorded at room 
temperature on a Perkin Elmer LS50B Luminescence Spectrometer in 1 
cm quartz cuvettes. The emission of BSA was measured in the range 
Δem=300-400 nm with an excitation wavelength of 288 nm. The excitation 
and emission slits were fixed at 5 nm, scanning speed 40 nm/min (10 
accumulations). 
    
 
 
 
 
 
X-Ray diffraction 
Single-crystal  data were collected with either a Bruker Smart APEXII area 
detector diffractometer (for IT05), or an Agilent Technologies Gemini E 
four-circle kappa diffractometer equipped with a 92 mm EOS CCD detector 
(for IT03/IT04), or a Philips PW1100 serial diffractometer (for Z-L-Pro-Aib-
OtBu), using MoK radiation (λ = 0.71073 Å) for the gold(III) complexes, 
while CuK (λ = 1.54178 Å) for the dipeptide. The structures were solved 
by direct methods (SIR2002[86a] or SIR2004[86b] programs) and refined by 
full-matrix least-squares procedures on F2 (SHELXL-14 program[87]), using 
the WinGX software package[88]. H-atoms were calculated at idealized 
positions and refined using a riding model. Graphical material was 
prepared with the ORTEP3 for Windows[89] and Mercury CSD 3.1[90] 
programs. Details specific to the individual structures are given below.  
IT05. The unit cell parameters were obtained using 60 ω-frames of 0.5° 
width and scanned from three different zone of reciprocal lattice. The 
intensity data were integrated from several series of exposures frames 
(0.3° width) covering the sphere of reciprocal space[86]. An absorption 
correction was applied using the program SADABS[86] with min. and max. 
transmission factors of: 0.676-1.000. The crystals were of poor quality and 
of small size, and this affected the overall quality of the data. For this 
reason, only the atoms comprising the coordination sphere were refined 
anisotropically, whereas the remaining atoms were refined isotropically. 
The hydrogen atoms were placed at their calculated positions. In the lattice, 
solvent molecules of crystallization (pentane) were found but could not be 
properly modelled during the refinement, and they were treated with the 
SQUEEZE program[74]. According to the residual electron density, the 
crystal lattice contained approximately one molecule of pentane per 
complex molecule. 
IT03/IT04. Crystals were grown by slow evaporation from an acetone 
solution containing equimolar amounts of the two enantiomers. Data 
collection and reduction were performed with the CrysAlisPro software 
(Agilent Technologies). A semi-empirical absorption correction based on 
the multi-scan technique using spherical harmonics, implemented in 
SCALE3 ABSPACK scaling algorithm, was applied. The structure contains 
co-crystallized solvent, which was eventually modeled as one acetone 
molecule disordered over two sites with population parameters of 0.60 and 
0.40, respectively. Many crystallographic parameters suffer from far-from-
optimal crystal size and quality. In particular, crystal decay occurred during 
data collection. Frames with R(int) > 0.20 were excluded from the dataset. 
As a consequence, data completeness is only 57%. Restraints were 
imposed to the bond distances involving the disordered solvent atoms, as 
well as to the anisotropic displacement parameters of most of the atoms 
outside the metal coordination shell, to approach isotropic behavior.  
Z-L-Pro-Aib-OtBu. The phenyl ring of the Z-group was constrained to the 
idealized geometry. The C atom of the Pro residue shows positional 
disorder. It was refined on two sites, CG1 and CG1, each with a population 
parameter of 0.50. Restrains were applied to the bond distances involving 
the disordered atoms. 
A summary of data collection and structure refinement for all the 
compounds is reported in the Supporting Information (Tables S2-S7  and 
Figures S8-S12). X-ray crystallographic data have been deposited at the 
Cambridge Crystallographic Data Center and allocated the deposition 
numbers CCDC 1001852 (IT05), CCDC 1031827 (Z-L-Pro-Aib-OtBu) and 
CCDC 1031828 (IT03/04) and the corresponding CIF files can be obtained 
free of charge from http://www.ccdc.cam.ac.uk. 
Synthesis 
The final purity of all the synthesized compounds was ≥95%, as 
determined by elemental and thermogravimetric analyses (see Supporting 
Information). 
General synthetic route for tert-Butyl- or TEG-esterified amino acids. Z-
Sar-OH, Z-L/D-Pro-OH, Z-L/D-Ala-OtBu, Z-Aib-OtBu were prepared 
according to literature methods.  
Z-Aib-OTEG. For the synthesis of Z-Aib-OTEG, 1 eq. of Z-Aib-OH (15 
mmol) is dissolved in CH2Cl2 and cooled to 0°C with ice bath. To the 
solution are added subsequently: 1.2 eq. of HOBt; 0.3 eq. of DMAP; 1.2 
equiv. di EDC; 2 eq. of TEG-OH, and the mixture is stirred for 48h. The 
solvent is evaporated at reduced pressure; the product is extracted with 
ethylacetate and washed with KHSO4 and NaHCO3 aqueous solutions. 
After removing water traces by treating with Na2SO4, the organic portion is 
dried obtaining a yellow oil which is purified by flash chromatography 
(eluent: petroleum ether/ethyl acetate 3:2 and subsequently 4.5:0.5, on 
silica). Yellow oil; yield: 92%; Rf1: 0.94; Rf2: 0.74; Rf3: 0.43. 1H NMR 
(300.13 MHz, DMSO-d6, 298 K, TMS): 1.55 (s, 6H, ß-CH3 Aib); 3.68 (s, 3H, 
O-CH3 TEG); 3.50-3.55, 3.60-3.68, 4.25-4.29 (m, 12H, -CH2 TEG); 5.08 
(s , 2H, -CH2 Z); 5.44 (s, 1H, N-H Aib); 7.27-7.36 (m, 5H, CH Z). FT-IR 
(KBr): ~ = 3341 (ν, N-H); 2984/2929/2877 (ν, C-H); 1739 (ν, C=O ester); 
1721 (ν, amide I); 1523 (ν, amide II); 1157 (ν, (TEG)-O).  
Synthetic route for tert-Butyl- or TEG-esterified dipeptide hydrochlorides 
and related intermediates. For the amino acids coupling reaction, generally, 
a THF solution (15–20 mL) of Z-Sar-OH is treated with NMM (22 mmol), 
cooled to −15 °C and then treated with isobutyl chloroformiate (22 mmol) 
under continuous stirring[46, 47]. After 10 min, a cold CHCl3 (10–35 mL) 
suspension of H-L/D-Ala-OtBu (or H-Aib-OtBu), H-Aib-OTEG; 22 mmol is 
added, adjusting the pH to ca. 8 by adding NMM. After stirring overnight at 
room temperature, the reaction mixture is concentrated under reduced 
pressure and the residue is dissolved with AcOEt, washed subsequently 
with 10% KHSO4, H2O, 5% NaHCO3, H2O, and dried over Na2SO4. For the 
Z-L/D-Pro-derivatives the coupling was achieved in CH2Cl2 by activating 
with EDC and HOBt. The organic layer is then concentrated to dryness 
and purified by flash chromatography using AcOEt/petroleum ether 1:1 as 
eluent, in order to obtain the corresponding Z-protected dipeptides esters 
(yield = 70–90%). Each Z-AA1-AA2-OR (AA1 = Pro, Sar; AA2 = Aib, Ala; R 
= tBu, TEG) intermediate is then Z-deprotected by catalytic hydrogenation 
over Pd/C (20% w/w) in MeOH. The H-AA1-AA2-OR compound is 
dissolved in dry diethylether and dropwise treated with 1 equivalent of a 
dilute ether solution of HCl (0.2 mM) under vigorous stirring, leading to the 
formation of a white precipitate corresponding to the hydrochloride form of 
the dipeptide, HCl.H-AA1-AA2-OR (AA1= Pro, Sar; AA2= Aib, Ala; R= t-Bu, 
TEG). 
HCl·H-Sar-D-Ala-OtBu (P1). White powder; yield: 65%. Rf1: 0.13; Rf2: 
0.23; Rf3: 0.04; m.p.: 148-150°C; [α]20D= 38.67° (c=0.5, MeOH); 1H NMR 
(300.13 MHz, DMSO-d6, 298 K, TMS): δ=9.00 [br, s, 2H, NH2+ Sar]. 8.88 
[d, 1H, NH Ala], 4.17 [m, 1H, α-CH Ala], 3.70 [s, 2H, N-CH2 Sar], 2.53 [s, 
3H, N-CH3 Sar], 1.40 [s, 9H, CH3 t-Bu], 1.28 ppm [d, 3H, β-CH3 Ala]; 
13C{1H} NMR (75.48 MHz, DMSO-d6, 298 K, TMS): δ= 171.27 (C=O Ala), 
164.86 (C=O Sar), 80.58 (-C(CH3)3 t-Bu), 48.53 (N-CH2 Sar), 48.29 (α-C 
Ala), 32.40 (N-CH3 Sar), 27.36 (CH3 t-Bu), 16.75 ppm (β-CH3 Ala); FT-IR 
(KBr): ~ =3332 (ν, N-H); 2978/2960/2936 (ν, C-H); 2763 (νa, NH2+);2701 
(νs, NH2+), 1735 (ν, C=O ester); 1669 (ν, amide I); 1564 (ν, amide II); 1266 
(ν, amide III); 1221 (ν, C-O(t-Bu)); 1165 cm-1 (ν, t-Bu-O). 
HCl·H-Sar-L-Ala-OtBu (P2). White powder; yield: 82%; Rf1: 0.13; Rf2: 
0.23; Rf3: 0.04; m.p.: 147-150°C; [α]20D = -39.1° (c = 0.5, MeOH); 1H NMR 
(300.13 MHz, DMSO-d6, 298 K, TMS): δ = 9.12 [br, s, 2H, NH Sar], 8.96 
[d, 1H, NH Ala], 4.16 [m, 1H, α-CH Sar], 3.69 [s, 2H, N-CH2 Sar], 2.52 [s, 
3H, N-CH3 Sar], 1.40 [s, 9H, CH3 t-Bu], 1.27 ppm [d, 3H, β-CH3 Ala]; 
13C{1H} NMR (75.48 MHz, DMSO-d6, 298 K, TMS): δ =171.22 (C=O Ala), 
164.87 (C=O Sar), 80.59 (-C(CH3)3 t-Bu), 48.52 (N-CH2 Sar), 48.29 (α-C 
Ala), 32.41 (N-CH3 Sar), 16.76 (β-CH3 Ala); 27.28 ppm (CH3 t-Bu); FT-IR 
(KBr): ~ =3332 (ν, N-H); 2978/2963/2939 (ν, C-H); 2766 (νa, NH2+); 2699 
(νs, NH2+); 1735 (ν, C=O ester); 1669 (ν, amide I); 1564 (ν, amide II); 1266 
(ν, amide III); 1220 (ν, C-O(t-Bu)); 1166 cm-1 (ν, t-Bu-O). 
HCl·H-D-Pro-Aib-OtBu (P3). White powder; yield: 49%; Rf1: 0.15; Rf2: 
0.30; Rf3: 0.06; m.p.: 104-108°C; [α]20D = -32.8° (c = 0.6, MeOH); 1H NMR 
(300.13 MHz, DMSO-d6, 298 K, TMS): δ=9.80 [s, br, 2H, NH2+ Pro]; 8.92 
    
 
 
 
 
 
[s, 1H, NH Aib], 4.11 [m, 1H, CH2 Pro], 3.15 [m, 2H, CH25 Pro], 2.27 [m, 
1H, CH3’ Pro], 1.83 [m, 3H, CH3’’ Pro e CH24 Pro], 1.32 [s, 9H, CH3 t-Bu], 
1.33, 1.36 ppm [2 s, 6H, β-CH3 Aib]; 13C{1H} NMR (75.48 MHz, DMSO-d6, 
298 K, TMS): δ = 172.15 (C=O Aib), 167.15 (C=O Pro), 79.65 (-C(CH3)3 t-
Bu), 58.07 (CH2 Pro), 55.69 (C(CH3)2 Aib), 45.32 (CH25 Pro), 29.59 (CH23 
Pro), 27.13 (CH3 t-Bu), 24.41 (CH3 Aib), 23.28 ppm (CH24 Pro); FT-IR 
(KBr):  =3430 (ν, N-H); 2979/2935 (ν, C-H); 2744 (νa,s, NH2+); 1733 (ν, 
C=O ester); 1678 (ν, amide I); 1551 (ν, amide II); 1256 (ν, amide III); 1219 
(ν, C-O(t-Bu)); 1146 cm-1 (ν, t-Bu-O).  
HCl·H-L-Pro-Aib-OtBu (P4). White powder; yield: 49%; Rf1: 0.15; Rf2: 
0.30; Rf3: 0.06; m.p.: 104-108°C. [α]20D = -31.2° (c = 0.7, MeOH); 1H NMR 
(300.13 MHz, DMSO-d6, 298 K, TMS): δ= 9.34 [s, br, 2H, NH2+ Pro], 8.94 
[s, 1H, NH Aib], 4.14 [m, 1H, CH2 Pro], 3.15 [m, 2H, CH25 Pro], 2.29 [m, 
1H, CH3' Pro], 1.83 [m, 3H, CH3'' and CH24 Pro], 1.37 ppm [2 s, 15H, β-
CH3 Aib and CH3 t-Bu]; 13C{1H} NMR (75.48 MHz, DMSO-d6, 298 K, TMS): 
δ = 172.06 (C=O Aib), 167.75 (C=O Pro), 79.65 (C(CH3)3 t-Bu), 58.26 (CH2 
Pro), 55.70 (C(CH3)2 Aib), 45.55 (CH25 Pro), 29.67 (CH23 Pro), 27.19 (CH3 
t-Bu), 24.50 (CH3 Aib), 23.56 ppm (CH24 Pro); FT-IR (KBr): ~ = 3437 (ν, N-
H); 2980/2936 (ν, C-H); 2744 (νa,s, NH2+); 1733 (ν, C=O ester); 1678 (ν, 
amide I); 1551 (ν, amide II); 1256 (ν, amide III); 1219 (ν, C-O(t-Bu)); 1146 
cm-1 (ν, (t-Bu)-O). 
HCl·H-Sar-Aib-OTEG (P5). Pale-yellow oil; yield: 97%; Rf1: 0.92; Rf2: 0.69; 
Rf3: 0.33; 1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ = 9.04 [s, 3H, 
NH Aib e NH2+ Sar], 4.10-4.13 [m, 2H, CH21 TEG], 3.66 [s, 2H, N-CH2 Sar], 
3.57-3.60 [m, 2H, CH22 TEG], 3.41-3.54 [m, 8H, CH23,4,5,6 TEG], 3.24 [s, 
3H, O-CH3 TEG], 2.51 [s, 3H, N-CH3 Sar], 1.39 ppm [s, 6H, β-CH3 Aib]; 
13C{1H} NMR (75.48 MHz, DMSO-d6, 298 K, TMS): δ =172.52 (C=O Aib), 
163.80 (C=O Sar), 68.8-70.7 (CH23,4,5,6 TEG), 67.44 (CH22 TEG), 63.19 
(CH21 TEG), 57.26 (O-CH3 TEG), 54.77 (C(CH3)2 Aib), 47.94 (N-CH2 Sar), 
31.84 (N-CH3 Sar), 23.39 (β-CH3 Aib); FT-IR (KBr): ~ =3193 (ν, N-H); 
2985/2937/2872 (ν, C-H); 2762 (νa,s, NH2+); 1739 (ν, C=O ester); 1684 (ν, 
amide I); 1554 (ν, amide II); 1256 (ν, amide III); 1217 (ν, C-OTEG); 1159 
(ν, (TEG)-O). 
General route for the synthesis of the complexes. The compound HCl·H-
AA1-AA2-OR (AA1= Sar, L/D-Pro; AA2= L/D-Ala, Aib; 0.7 mmol) is 
dissolved in water and the solution was kept at 0°C with a water/ice bath. 
Under continuous stirring, cold CS2 (1.4 mmol) and sodium hydroxide (0.7 
mmol) are added to the solution. The variation of pH from 9 to 6 confirms 
the reaction of the dipeptide with CS2 and the consequent formation of the 
dithiocarbamato derivative. The ligand solution is then added, under 
vigorous stirring, to an ice-cold water solution of K[AuIIIBr4] (0.35 mmol), 
leading to the formation of a yellow ochre-brown precipitate. The solid is 
separated from the mother liquor and washed several times with ice-cold 
water, then purified by flash chromatography and dried under reduced 
pressure with P2O5. 
[AuIIIBr2(SSC-Sar-L-Ala-OtBu)] (ITØ1, dibromido[1-(1,1-
dimethylethyl) N-dithiocarboxy-S,S')-N-methylglycil-(S)-
alaninato]gold(III)). Ochre powder; yield: 86%;  
1H NMR (300.13 MHz, acetone-d6, 298 K, TMS): δ=7.93 (d, 1H, NH Ala), 
4.71 (s, 2H, NCH2 Sar), 4.37 (m, 1H, CH Ala), 3.54 ( s, 3H, NCH3 Sar), 
1.45 (s, 9H, CH3 tBu), 1.36 ppm (d, 3H, CH3 Ala); 1H NMR (300.13 MHz, 
DMSO-d6, 298 K, δ/ppm, TMS): 8.79 (m, 1H, NH Ala), 4.53 (m, 2H, NCH2 
Sar), 4.18 (m, 1H, CH Ala), 3.37 (s, 3H, NCH3 Sar), 1.40 (s, 9H, CH3 tBu), 
1.23 ppm (d, 3H, CH3 Ala); 13C{1H} NMR (75.48 MHz, acetone-d6, 298 K, 
TMS): δ =198.2 (CSS), 172.54 (C=O Ala), 164.72 (C=O Sar), 82.36 
(C(CH3)3 tBu), 55.5 (NCH2 Sar), 50.35 (CH Ala), 40.5 (NCH3 Sar), 28.35 
(CH3 tBu), 18.34 (CH3 Ala); IR (KBr):  =3317 (ν, N-H); 2979/2932 (ν, C-
H); 1733 (ν, C=O ester); 1668 (ν, amide I); 1564 (n, N-CSS+amide II); 1219 
(ν, C-O(tBu)+amide III); 1149 (ν, (tBu)-O); 1003 cm-1 (νa, S-C-S). FT-IR 
(nujol): ~ =567 (νs, S–C–S); 419 (νa, S–Au–S); 380 (νs, S–Au–S); 251 (νa, 
Br–Au–Br); 229 cm-1 (νs, Br–Au–Br). Elemental analysis: calcd (%) for 
C11H19AuBr2N2O3S2 (648.19 g mol-1): C, 20.38; H, 2.95; N, 4.32; S, 9.89%; 
found: C, 20.52; H, 2.93; N, 4.41; S, 9.90%. TG (air): calcd weight loss to 
Au(0) - 69.6%; found - 68.0%. 
[AuIIIBr2(SSC-Sar-D-Ala-OtBu)] (ITØ2, dibromido[1-(1,1-
dimethylethyl) N-dithiocarboxy-S,S')-N-methylglycil-(R)-
alaninato]gold(III)). Ochre powder; yield: 86%;  
1H NMR (300.13 MHz, acetone-d6, 298 K, TMS): δ=7.94 (d, 1H, NH Ala), 
4.69 (s, 2H, NCH2 Sar), 4.37 (m, 1H, CH Ala), 3.53 ( s, 3H, NCH3 Sar), 
1.45 (s, 9H, CH3 tBu), 1.36 (d, 3H, CH3 Ala); 1H NMR (300.13 MHz, DMSO-
d6, 298 K, TMS): δ =8.79 (m, 1H, NH Ala), 4.53 (m, 2H, NCH2 Sar), 4.17 
(m, 1H, CH Ala), 3.36 (s, 3H, NCH3 Sar), 1.41 (s, 9H, CH3 tBu), 1.28 (d, 
3H, CH3 Ala); 13C{1H} NMR (75.48 MHz, acetone-d6, 298 K, TMS): 
δ=197.72 (CSS), 171.88 (C=O Ala), 163.81 (C=O Sar), 81.70 (C(CH3)3 
tBu), 54.83 (NCH2 Sar), 49.68 (CH Ala), 39.9 (NCH3 Sar), 27.69 (CH3 tBu), 
17.67 (CH3 Ala); FT-IR (KBr):  =3311 (ν, N-H); 2979/2933 (ν, C-H); 1732 
(ν, C=O ester); 1668 (ν, amide I); 1563 (ν, N-CSS+amide II); 1218 (ν, C–
O(tBu)+amide III); 1149 (ν, (tBu)-O); 1003 (νa, S-C-S). IR (nujol): ~ =566 
(νs, S–C–S); 419 (νa, S–Au–S); 380 (νs, S–Au–S); 251 (νa, Br–Au–Br); 228 
cm-1 (νs, Br–Au–Br). Elemental Analysis calcd (%) for C11H19AuBr2N2O3S2 
(648.19 g mol-1): C, 20.38; H, 2.95; N, 4.32; S, 9.89%; found: C, 19.96; H, 
2.86; N, 4.55; S, 9.89%. TG (air): calcd weight loss to Au(0) - 69.6%; found 
- 67.9%. 
[AuIIIBr2(SSC-L-Pro-Aib-OtBu)] (ITØ3, dibromido[1-(1,1-
dimethylethyl) N-dithiocarboxy-S,S')-N(S)-prolyl-2-
methylalaninato]gold(III)). Dark-orange powder. Yield: 76%.; 1H NMR 
(300.13 MHz, acetone-d6, 298 K, TMS): δ=8.01 (s, br, 1H, NH Aib), 4.92 ( 
m, 1H, CH2 Pro), 3.98 (m, 2H, CH25 Pro), 2.57ù9 (m, 1H, CH3' Pro), 2.32 
(m, 3H, CH24 + CH3’’ Pro), 1.44 (s, 9H, CH3' tBu), 1.45 ppm (s, 6H, CH3 
Aib); 1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ=8.75 (m, 1H, NH 
Aib), 4.76 (m, 1H, CH2 Pro), 3.88 (m, 2H, CH25 Pro), 2.41 (m, 1H, CH3' 
Pro), 2.08 (m, 3H, CH24 + CH3’’ Pro), 1.38 (s, 9H, CH3 t-Bu), 1.33 ppm (s, 
6H, CH3 Aib); 13C{1H} NMR (75.48 MHz, acetone-d6, 298 K, TMS): 
δ=190.22 (-CSS), 172.84 (C=O Aib), 166.69 (C=O Pro), 80.98 (C(CH3)3 
tBu), 64.87 (CH2 Pro), 57.28 (C(CH3)2 Aib), 52.10 (CH25 Pro), 30.84 (CH23 
Pro), 28.00 (CH3 t-Bu), 25.01 (CH3 Aib), 23.09 (CH24 Pro); IR (KBr): 
=3341 (ν, N-H); 2979/2931 (ν, C-H); 1730 (ν, C=O ester); 1680 (ν, amide 
I); 1553 (ν, N-CSS amide II); 1247 (ν, C-O(tBu)+amide III); 1147 (ν, (tBu)-
O); 1000 cm-1 (νa, S-C-S). FT-IR (nujol): ~ =535 (νs, S–C–S); 410 (νa, S–
Au–S); 376 (νs, S–Au–S); 252 (νa, Br–Au–Br); 222 cm-1 (νs, Br–Au–Br). 
Elemental Analysis calcd (%) for C14H23AuBr2N2O3S2 (688.26 g mol-1): C, 
24.43; H, 3.37; N, 4.07; S, 9.32%; found: C, 24.59; H, 3.47; N, 4.14; S, 
8.98%. TG (air): calcd weight loss to Au(0) - 71.4%; found - 72.0%. 
[AuIIIBr2(SSC-D-Pro-Aib-OtBu)] (ITØ4, dibromido[1-(1,1-
dimethylethyl) N-dithiocarboxy-S,S')-N(R)-prolyl-2-
methylalaninato]gold(III)). Dark-orange powder; obtained as described 
for the synthesis of IT03. Yield: 25%; 1H NMR (300.13 MHz, acetone-d6, 
298 K, TMS): δ=8.00 (s, br, 1H, NH Aib), 4.92 ( m, 1H, CH2 Pro), 3.98 (m, 
2H, CH25 Pro), 2.58 (m, 1H, CH3' Pro), 2.33 (m, 3H, CH24 + CH3'' Pro), 1.44 
(s, 9H, CH3 tBu), 1.45 (s, 6H, CH3 Aib); 1H NMR (300.13 MHz, DMSO-d6, 
298 K, TMS): δ=8.78 (s, br, 1H, NH Aib), 4.76 (m, 1H, CH2 Pro), 3.89 (m, 
2H, CH25 Pro), 2.41 (m, 1H, CH3' Pro), 2.10 (m, 3H, CH24 + CH3'' Pro), 1.38 
(s, 9H, CH3 t-Bu), 1.31 (s, 6H, CH3 Aib). 13C{1H} NMR (75.48 MHz, 
acetone-d6, 298 K, TMS): δ=190.21 (-CSS), 172.96 (C=O Aib), 166.94 
(C=O Pro), 81.10 (C(CH3)3 tBu), 64.92 (CH2 Pro), 57.44 (C(CH3)2 Aib), 
52.08 (CH25 Pro), 30.80 (CH23 Pro), 27.97 (CH3 tBu), 24.95 ppm (CH3 Aib), 
23.16 (CH24 Pro); IR (KBr):  =3363 (ν, N-H); 2982/2927 (ν, C-H); 1732 (ν, 
C=O ester); 1680 (ν, amide I); 1549 (ν, N-CSS+amide II); 1241 (ν, C-
O(tBu)+amide III); 1147 (ν, (tBu)-O); 991 cm-1 (νa, S-C-S). FT-IR (nujol): ~
=533 (νs, S–C–S); 410 (νa, S–Au–S); 376 (νs, S–Au–S); 251 (νa, Br–Au–
Br); 222 cm-1 (νs, Br–Au–Br). Elemental analysis calcd (%) for 
C14H23AuBr2N2O3S2 (688.26 g mol-1): C, 24.43; H, 3.37; N, 4.07; S, 9.32%; 
found: C, 24.30; H, 3.64; N, 4.06; S, 9.02%. TG (air): calcd weight loss to 
Au(0) - 71.4%; found - 71.9%. 
[AuIIIBr2(SSC-Sar-Aib-OTEG)] (ITØ5, dibromido[1-(1,1-dimethylethyl) 
N-dithiocarboxy-S,S')-N-methylglycil-2-methylalaninato]gold(III)). 
After the general synthetic procedure previously described, the compound 
was further purified to eliminate the presence of hydrolyzed compound at 
the ester function, by dissolving the product in dichloromethane and 
washing it with a water solution of KHCO3 5%.  
    
 
 
 
 
 
Dark-brown powder, Yield: 56%. 1H NMR (300.13 MHz, acetone-d6, 298 
K, TMS): δ=8.05 (s, br, 1H, NH Aib), 4.64 (s, 2H, NCH2 Sar), 4.19-4.22 (m, 
2H, CH21 TEG), 3.65-3.68 ( m, 2H, -CH22 TEG), 3.51 (s, 3H, NCH3 Sar), 
3.47-3.62 (m, 8H, CH23,4,5,6 TEG), 3.29 (s, 3H, OCH3 TEG), 1.50 ppm (s, 
6H, CH3 Aib); 1H NMR (300.13 MHz, DMSO-d6, 298 K, TMS): δ=8.83 (s, 
br, 1H, NH Aib), 4.47 (s, 2H, NCH2 Sar), 4.10-4.11 (s, br, 2H, -CH21 TEG), 
3.62-3.65 (2H, -CH22 TEG),  3.36-3.58 (m, 11H, CH23,4,5,6 TEG, NCH3 Sar), 
3.24 (s, 3H, OCH3 TEG), 1.39 (s, 6H, CH3 Aib); 13C{1H} NMR (75.48 MHz, 
acetone-d6, 298 K, TMS): δ=197.3 (CSS), 173.63 (C=O Aib), 163.54 (C=O 
Sar), 70.8-71.2 (CH23,4,5,6 TEG), 69.25 (CH22 TEG), 64.52 (CH21 TEG), 
58.52 (OCH3 TEG), 57.00 (C(CH3)2 Aib), 54.84 (NCH2 Sar), 39.86 (NCH3 
Sar), 24.86 (CH3 Aib); FT-IR (KBr): ~ =3290 (ν, N-H); 2909/2872 (ν, C-H); 
1735 (ν, C=O ester); 1683 (ν, amide I); 1576 (ν, N-CSS); 1549 (ν, amide 
II); 1253 (ν, amide III); 1210 (ν, C–OTEG); 1159  (ν, TEG-O); 1022 cm-1 
(νa, S-C-S). IR (nujol):  =569 (νs, S-C-S); 412 (νa, S-Au-S); 390 (νs, S-Au-
S); 250 (νa, Br-Au-Br); 226 cm-1 (νs, Br-Au-Br). Elemental analysis calcd 
(%) for C15H27AuBr2N2O6S2 (752.30 g mol-1): C, 23.95; H, 3.62; N, 3.72; 
S, 8.52%; found: C, 24.40; H, 3.55; N, 3.70; S, 8.57%. TG (air): calcd 
weight loss to Au(0) - 72.6%; found - 73.8%. 
Cell lines 
The human breast adenocarcinoma cancer cell line MCF7, the human lung 
cancer cell line A549 and the human ovarian cancer cell line A2780 
(obtained from the European Centre of Cell Cultures ECACC, Salisbury, 
UK) were cultured respectively in DMEM (Dulbecco’s Modified Eagle 
Medium) and RPMI containing GlutaMaxI supplemented with 10% FBS 
and 1% penicillin/streptomycin (all from Invitrogen), at 37°C in a humidified 
atmosphere of 95% of air and 5% CO2 (Heraeus, Germany).  
Human non-small cell lung cancer cell line H1975 and human epidermoid 
carcinoma cell line A431 (obtained from the American type culture 
collection (ATCC)) were grown in RPMI-1640 medium (Sigma Aldrich) and 
in Dulbecco's modified Eagle's medium (DMEM, Sigma Aldrich) 
supplemented with D-glucose (final concentration 4.5 g/L, Sigma), 
respectively. Large cell lung carcinoma cell line H460 was grown in RPMI 
1640 (Sigma Chemical Co.) supplemented with 2.38 g/L Hepes, 0.11 g/L 
pyruvate sodium and 2.5 g/L glucose, 1.5 g/L NaHCO3, 10% Heat-
inactivated fetal calf serum (Invitrogen), 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 0.25 μg/mL amphotericin B (Sigma Chemical Co.) were 
added to the media. The cells were cultured at 37°C in a moist atmosphere 
of 5% carbon dioxide in air. 
 
 
In vitro cell viability assays 
For the cell lines A549, MCF7 and A2780, cells in an exponential growth 
rate were seeded (8,000 cells per well) in 96-well plates (Costar 3595) and 
grown for 24 h in complete medium. Solutions of the compounds were 
prepared by diluting a stock solution (10-2 M in DMSO for the gold 
complexes, saline solution in the case of cisplatin) in culture medium 
(DMSO or ethanol in the culture medium never exceeded 1% v/v). 
Subsequently, different dilutions of the compounds were added to the wells 
to obtain a final concentration from 0.5 to 100 μM.  
Conversely, H1975, A431 and H460 cells (3-4 x 104) were seeded into 
each well of a 24-well cell culture plate. After incubation for 24 h, the 
medium was replaced with an equal volume of fresh medium, and various 
concentrations of the test complexes were added. The cells were  then  
incubated  in  standard  conditions  for  further  72  hours.  Stock  solutions  
of  all  complexes  were made in dimethyl sulfoxide and then diluted with 
complete medium in such a way that the final amount of  solvent  in  each  
well  did  not  exceed  0.4%  v/v.  Cisplatin  (Sigma) was  dissolved  in  
saline  solution (0.9% w/v NaCl)  up  to  4  mM  and  then  added  to  each  
well  at  the  indicated  concentration.   
Following 72 h of exposure, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was added to the cells at a final 
concentration of 0.50 mg/mL in PBS (phosphate buffered saline solution, 
pH 7.4) and incubated for 2.5 h. The incubation medium was removed and 
the violet formazan crystals in the cells were dissolved in DMSO, and the 
optical density of each well was quantified at 550 nm, using a multi-well 
plate reader (ThermoMax microplate reader, Molecular devices, US). The 
percentage of surviving cells was calculated from the ratio of absorbance 
between treated and untreated cells. Each treatment was performed in 
quadruplicate. 
Cytotoxicity  data  were  expressed  as  GI50 values, i.e. the  concentration  
of  the  test  complex  inducing  50%  reduction  in  cell  number  compared  
with  control cultures. 
 
 
 
Preparation of rat Precision-Cut Kidney Slices (PCKS) and toxicity 
studies ex vivo 
Male Wistar rats (Charles River, France) of 250-300 g were housed under 
a 12 h dark/light cycle at constant humidity and temperature. Animals were 
permitted ad libitum access to tap water and standard lab chow. All 
experiments were approved by the Committee for care and use of 
laboratory animals of the University of Groningen and were performed 
according to strict governmental and international guidelines. Tissues 
were harvested (from rats anesthetized with isoflurane) and immediately 
placed in University of Wisconsin solution (UW, ViaSpan, 4⁰ C) until further 
use. PCTS were made as described by de Graaf et al.[25,26] 
In brief, the intestine tissue was flushed with ice-cold Krebs-Henseleit 
buffer. After the removal of the muscle layer, a segment of 10 × 20 mm 
was embedded in 3% agarose (low-gelling-temperature agarose type VII, 
Sigma-Aldrich, Steinheim, Germany) using a tissue embedding unit. Cores 
of tissue were prepared from liver and kidney using a coring tool. 
Specifically, after removing fat, kidneys were cut in half lengthwise using a 
scalpel, and cortex cores of 5 mm diameter were made from each half 
perpendicular to the cut surface using disposable Biopsy Punches (KAI 
medical, Japan). Rat intestine, liver and kidney tissues were subsequently 
sliced with a Krumdieck tissue slicer (Alabama R&D, Munford, AL, USA) 
in ice-cold Krebs-Henseleit buffer pH 7.4,  saturated with carbogen (95% 
O2 and 5% CO2). Intestinal slices (350-450 µm thick and 2-4 mg wet 
weight) and liver and kidney slices (250 µm thick and 4 mg wet weight) 
were stored in ice-cold Krebs-Henseleit buffer until incubation.  
PCTS were incubated in 12-well plates (Greiner bio-one GmbH, 
Frickenhausen, Austria) individually at 37°C, in 1.3 mL Williams’ medium 
E (WME, Gibco by Life Technologies, Paisley, UK) with glutamax-1, 
supplemented with 25 mM D-glucose (Gibco) and antibiotics (liver: 50 
µg/mL gentamicin (Gibco); colon: 50 µg/mL gentamycin + 2.5 ug/mL 
amphotericin B; kidney: 10 µg/mL ciprofloxacin HCl) at pH 7.4 in an 
incubator (Panasonic biomedical) in an atmosphere of 80% O2 and 5% 
CO2 with shaking (90 times/min). 
Stock solutions of compounds IT03, AuL12 and cisplatin were prepared as 
for the studies on cell lines. The final concentration of DMSO during the 
PCTS incubation was always below 1% v/v to exclude solvent toxicity. For 
each concentration, three slices were incubated individually for one hour 
in WME and subsequently, different dilutions of the compounds were 
added to the wells, to obtain a final concentration from 0.5 to 100 μM. After 
this, kidney and liver were incubated for 24 h. After the incubation, slices 
were collected for ATP and protein determination, by snap freezing them 
in 1 mL of ethanol (70% v/v) containing 2 mM EDTA with pH=10.9. After 
thawing, the slices were homogenized using a mini-bead beater and 
centrifuged. The supernatant was used for the ATP essay and the pellet 
was dissolved in 5N NaOH for the protein essay. The viability of PCTS was 
determined by measuring the ATP using the ATP Bioluminescence Assay 
kit CLS II (Roche, Mannheim, Germany) as described previously.[25,26] The 
ATP content was corrected by the protein amount of each slice and 
expressed as pmol/μg protein. The protein content of the PCTS was 
determined by the Bio-Rad DC Protein Assay (Bio-Rad, Munich, Germany) 
using bovine serum albumin (BSA, Sigma-Aldrich, Steinheim, Germany) 
for the calibration curve. The TC50 value was calculated as the toxic 
concentration reducing the viability of the slices by 50% with respect to the 
control, in terms of ATP content corrected by the protein amount of each 
slice and relative to the slices without any treatment (using 5 h vehicle 
control or the 24 h vehicle control for intestine or liver/kidney tissue, 
respectively), and is presented as a mean (± SD) of at least three 
independent experiments.  
 
PARP-1 activity determinations 
PARP-1 activity was determined using Trevigen's HT Universal 
Colorimetric PARP Assay. This assay measures the incorporation of 
biotinylated poly(ADP-ribose) onto histone proteins in a 96 microtiter strip 
well format. Recombinant human PARP-1 (High Specific Activity, purified 
from E.coli containing recombinant plasmid harbouring the human PARP 
    
 
 
 
 
 
gene, supplied with the assay kit) was used as the enzyme source. 3-
Aminobenzamide (3-AB), provided in the kit, was used as control inhibitor. 
Two controls were always performed in parallel: a positive activity control 
for PARP-1 without inhibitors, that provided the 100% activity reference 
point, and a negative control, without PARP-1 to determine background 
absorbance. PARP-1 was incubated with different concentrations of 
compounds for 1 h or 24 h at RT prior deposition on the plate wells. The 
final reaction mixture (50 L) was treated with TACS-Sapphire™, a 
horseradish peroxidase colorimetric substrate, and incubated in the dark 
for 30 min. Absorbance was read at 630 nm after 30 min. The data 
correspond to means of at least three experiments performed in triplicate 
 S.D. 
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